Intuity Medical’s POGO Automatic® Blood Glucose Monitoring System
FREMONT, Calif. and PARSIPPANY, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) — Intuity Medical, Inc. and Embecta Corp. (“embecta”) (NASDAQ: EMBC) today announced they have signed a co-promotional agreement under which embecta sales representatives will be able to promote Intuity Medical’s innovative POGO Automatic® Blood Glucose Monitoring System to healthcare professionals they call on within the U.S., effective immediately.
Both companies are dedicated to improving the lives of people with diabetes. Having spun off from BD (Becton, Dickinson and Company) in April of this year, embecta is one of the world’s largest pure-play diabetes companies and, with a nearly 100-year history of leadership in insulin delivery, well established across the U.S. market. Intuity Medical is a medical technology company focused on the development and commercialization of seamless and intuitive blood glucose monitoring solutions.
“We are excited to partner with an established leader like embecta that has such extensive experience serving people with diabetes,” said George Zamanakos, President and CEO of Intuity Medical. “Working closely with the embecta team will help us expand where we’re able to offer POGO Automatic, giving a new option for simplifying diabetes to millions of people currently relying on conventional blood glucose meters.”
With its 10-test cartridge technology, POGO Automatic is the only FDA-cleared automatic blood glucose monitor (ABGM) that lances, collects blood, and produces a glucose result at the push of one button, ending the need to individually load and then dispose of lancets and test strips. Being able to offer POGO Automatic will expand the innovation and breadth of embecta’s diabetes care offerings.
“The agreement to promote POGO Automatic to healthcare professionals not only enables us to expand our offerings to physicians we call on, but it does so within an innovative new category,” said Tom Blount, Senior Vice President and President, North America, for embecta. “Automatic blood glucose monitoring is transforming this vital aspect of self-management into something truly seamless and simple for people with diabetes.”
About Intuity Medical, Inc.
Intuity Medical, Inc. is a commercial-stage medical technology company focused on developing innovative solutions to improve the health and quality of life of people with diabetes. Headquartered in Fremont, California, the company strives to simplify diabetes management and was founded with the mission of making life with diabetes easier. Intuity Medical’s POGO Automatic® Blood Glucose Monitoring System is the only FDA-cleared automatic blood glucose monitoring system that lances and collects blood in just one step with 10-test cartridge technology, ending the need to individually load lancets and test strips (as required by conventional blood glucose meters). POGO Automatic delivers a much simplified and discreet blood glucose testing experience that is less disruptive to the everyday lives of people with diabetes. To learn more, please visit www.presspogo.com.
About embecta
embecta, formerly part of BD (Becton, Dickinson and Company), is one of the largest pure-play diabetes care companies in the world, leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com.
CONTACTS
Media (for Intuity Medical):
Jeff Christensen
831-566-0275
publicrelations@intuitymedical.com
Media (for embecta):
Christian Glazar
Sr. Director, Corporate Communications
908-821-6922
Contact Media Relations
embecta Investors:
Pravesh Khandelwal
VP, Head of Investor Relations
551-264-6547
Contact IR
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3dad0bdb-c92d-4dd4-834e-12f508ea494d
Related Quotes
Becton, Dickinson and Company's ( NYSE:BDX ) price-to-earnings (or "P/E") ratio of 33.1x might make it look like a…
U.S. Food and Drug Administration staff said on Monday Veru Inc's experimental drug for COVID-19 met the main goal of reducing the death rate in a late-stage trial, but flagged a number of uncertainties with the data. Staff reviewers said the data did not help in clearly identifying a relevant patient population and remained unclear about the mortality rate in the placebo group. Veru has applied for emergency use authorization for its drug, sabizabulin, as a treatment for hospitalized moderate-to-severe COVID patients at high risk of developing an acute respiratory distress syndrome.
Staff reviewers said the data did not help in clearly identifying a relevant patient population and remained unclear about the mortality rate in the placebo group. Veru has applied for emergency use authorization for its drug, sabizabulin, as a treatment for hospitalized moderate-to-severe COVID patients at high risk of developing an acute respiratory distress syndrome. The application is based on data from a study involving 210 patients that showed sabizabulin led to a 55.2% reduction in death rates versus placebo.
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today reported interim results from the phase 1/2 GOBLET study's first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) cohort in an abstract published as part of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting. The SITC meeting is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA, from November 8 – 12, 2022.
Now, investors want to know whether DexCom can continue riding that wave for a while — and there are good reasons why it might. DexCom develops continuous glucose monitoring (CGM) devices that help diabetes patients with an essential function: tracking their blood sugar levels. CGM devices like DexCom's G6 compete with blood glucose meters (BGM) in helping people with diabetes with this critical task.
China's strict zero-COVID policy was making headlines Monday after Apple and iPhone manufacturer Foxconn said over the weekend that restrictions will delay shipments of the iPhone 14.
Village Practice Management would combine with Summit Health, the parent company of CityMD urgent-care centers, in an agreement that could be reached as early as Monday, people familiar with the matter said.
Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the presentation of new data from the Phase 3 RAPID clinical trial of etripamil, the Company's investigational calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT) in the at-home setting. The presentation, titled "Self-administered Etripamil for Termination of Spontaneous Paroxysmal
The star of "The Good Place" told her Instagram followers that the so-called "heroin chic" look caused "millions of eating disorders."
(Bloomberg) — VillageMD, a primary-care provider controlled by Walgreens Boots Alliance Inc., has agreed to acquire the parent of CityMD, the urgent-care center chain. Most Read from BloombergTwitter Now Asks Some Fired Workers to Please Come BackHouston Mogul’s $75 Million Win on Astros Hits Caesars HardestElon Musk Walks Back on Twitter Job Cuts, Blue Checks in Second WeekUkraine Latest: US and Russia Discussed Containing War, WSJ SaysCOP27 Latest: Coal Deal Provides Counterpoint to Record De
Organon (NYSE: OGN), a global women's health company, is announcing the launch and product availability of Aybintio®, a biosimilar of Avastin®, providing a new treatment option for adult Canadian patients affected with certain aggressive forms of cancers, including metastatic colorectal cancer (mCRC), locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC), platinum-sensitive recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer, platinum-resistant recur
Scientists are hopeful that the lab-grown blood could perform better than blood collected directly from donors.
Don't throw away your one shot.
As a new study confirms drinking too much really does make you look older, Lisa Salmon looks into other lifestyle factors that may contribute too
Whether you're dealing with belly rolls, a beer gut, or the middle-aged spread, it's safe to say your midsection situation is cramping your vibe—and putting your health at risk. Excess waistline fat makes squeezing into your favorite pants or shorts quite the chore, and you'd like to shape things up. To get you started, we've put together a bodyweight workout that'll help you lose five inches off your waist with no equipment required.According to the Mayo Clinic, abdominal fat should not be take
LET’S UNPACK THAT: Studies have shown that the majority of men display signs of some form of body dysmorphia, while hyper-jacked actors such as Channing Tatum and Zac Efron have expressed regret over their unhealthy workout regimes. Are we in the midst of a male body-image crisis, asks Matthew Neale
By Ernest Dela Aglanu, Benzinga
Alcohol, including white wine, can be part of a healthy lifestyle if you choose to drink. According to the 2020-2025 Dietary Guidelines for Americans, if you opt to include alcohol in your diet, then it's suggested that you drink it in moderation.The recommendation for moderate consumption is up to 2 drinks per day for men and up to 1 drink per day for women. But what exactly is considered one drink of white wine and what happens to your body when you drink white wine on a nightly basis?One serv
New studies show that ultra-processed foods are linked to cancer, mortality and poor mental health. Examples of ultra processed foods and how to avoid processed foods.
Amy Schumer has revealed that her 3-year-old son, Gene, was taken to the emergency room this week and treated for respiratory syncytial virus.